25 August 2015 in Current Pediatrics
LNL. S. Namazova-Baranova
+2
Болезнь Фабри — тяжелое прогрессирующее наследственное заболевание, которое относится к лизосомным болезням накопления и является одной из форм сфинголипидозов. Болезнь Фабри часто дебютирует в детском и подростковом возрасте, хотя полная клиническая картина манифестирует у взрослых пациентов. Ранняя диагностика этого заболевания во многих случаях весьма сложна из-за полиморфной клинической картины, неспецифичности многих начальных симптомов и малой осведомленности медицинских работников по данной проблеме. Пациентам с болезнью Фабри проводят специфическую патогенетическую ферментозаместительную терапию. При своевременной постановке диагноза и быстром начале лечения это позволяет повысить как продолжительность, так и качество жизни больных.
6 December 2020 in Neuromuscular Diseases
Introduction. Spinal muscular atrophy is a severe neuromuscular disease characterized by rapid progression of muscle weakness and early death. Pathogenetic therapy with nusinersen can significantly change the course of the disease and enable the patient to acquire new skills. The study of the efficacy and safety of nusinersen therapy in patients with type 1 spinal muscular atrophy should be continued. The aim of the study was to assess the safety and efficacy of nusinersen therapy in patients with type 1 spinal muscular atrophy for 6 months as part of an expanded access program at federal and regional healthcare facilities. Materials and methods. Patients with type 1 spinal muscular atrophy received nusinersen therapy under the expanded access program (NCT02865109). Patients were evaluated before starting treatment and 6 months after starting treatment. Overall motor development and motor function was assessed using the Hammersmith Infant Neurological Status Scale Part 2 and the Philadelphia Pediatric Hospital Neonatal Motor Scale. Results. 41 children aged 6 to 38 months received nusinersen therapy between July 2019 and March 2020. At the time of analysis, all patients were alive and continued treatment. The average improvement on the Hammersmith Hospital Neurological Status Scale was 3.7 points after 6 months of therapy compared to baseline (n = 39, p 0.001). The mean improvement on the Children’s Hospital of Philadelphia Scale for the Diagnosis of Motor Function in Newborns was 9.8 after 6 months of therapy from baseline (n = 30, p 0.001). Conclusion. The efficacy and safety of nusinersen have been demonstrated in real clinical practice in Russia in the treatment of early-onset spinal muscular atrophy.
27 March 2020 in Russian Pediatric Journal
Introduction. Knowledge of the prevalence of autism in children is a prerequisite for the organization of medical and social care for this population of patients. Aim: to determine the prevalence of autism among the children of the Russian Federation of different age groups according to official statistics. Materials and methods. An analysis of official data on the incidence and prevalence of disability in autism in children of different age groups (0-4 years, 5-9, 10-14 and 15-17 years) for the period 2016-2018 was carried out. The share of autism in the structure of morbidity and disability caused by mental disorders and behavioral disorders was determined. Results. There has been an increase in cases of autism diagnosis among the child population, extremely significant among adolescents aged 15-17. The age structure of autism cases has changed - the proportion of children aged 0-4, 5-9 and the proportion of adolescents aged 15-17 has significantly decreased. The prevalence of autism-related disability compared to morbidity has not increased as significantly. Its highest rates were among children aged 5-9. Due to the sharp increase in autism cases, the proportion of persons with disabilities among them has decreased several times. The incidence of autism in the structure of morbidity and disability caused by mental disorders and behavioral disorders in children aged 0-17 has increased. Conclusion. The obtained data can be used in the organization of medical and social care for children suffering from autism. The need for special epidemiological studies to determine the true prevalence of autism in children seems relevant.
30 April 2025 in L.O. Badalyan Neurological Journal
Introduction. The advent of pathogenetic therapy has significantly changed the prognosis for spinal muscular atrophy (SMA). However, our knowledge of the pathogenetic methods of treating SMA is mostly based on the results of clinical trials, which are largely limited due to the narrow criteria for selecting patients and the short duration of the following-up. Objective. To evaluate the efficacy of onasemnogene abeparvovec gene therapy in patients with SMA type I with clinical manifestations of the disease and in children at the presymptomatic stage of the disease in real clinical practice. Materials and methods. The study included seventy nine SMA children including 42 boys (53.2%). The diagnosis was verified during DNA diagnostics. The children were divided into two subgroups, depending on whether they had symptoms of SMA at the time of inclusion in the study or not. 44 children had SMA type I with the onset of clinical symptoms before the age of 6 months of life. 35 children were at the presymptomatic stage of the disease. All patients received gene therapy with onasemnogene abeparvovec, the average age at the moment of conduction of therapy was 2.90 ± 1.74 months (95% CI: 2.51–3.29 months), min — 1.00 month, max — 7.00 months. A comprehensive assessment of clinical parameters (stages of motor development milestones according to WHO recommendations, HINE-2 and CHOP-INTEND scores) was carried out before the initiation of gene therapy and 6, 12, 18 and 24 months after its implementation. Results. Children with SMA type I showed favour trend in motor development milestones after gene therapy. By the end of the second year of the follow-up, 88.6% of patients held their head erect and rolled from back to sides; 60.5% could sit without support, but only 10.3% were able to achieve all motor skills, but none of these children achieved them in accordance with WHO criteria. The HINE-2 score increased from Me of 2.0 (1.00–2.25) points at the initiation of therapy to Me of 20.00 (16.50-24.50) points by the end of the follow-up period. Only two children (4.5%) of this subgroup reached the maximum score of 26 points. The CHOP-INTEND score increased from Me of 30.0 (22.00–37.25) points before starting treatment to Me of 60.0 (58.0-64.0) points by 24 months of follow-up. Only 11.4% of patients with SMA type I reached the maximum score of 64 points. The majority of the presymptomatic patients in our study achieved all motor development milestones according to WHO criteria according to their age on the background of gene therapy. All children from this subgroup who were under sufficient supervision and reached the age of walking alone (23 children) had a maximum HINE-2 score of 26 points by the age of 18 months. All children from this subgroup reached the maximum CHOP-INTEND score of 64 points by the age of 6 months. Conclusion. The usage of onasemnogene abeparvovec in children with SMA type I both significantly modifies the course of the disease and improves outcomes compared with the natural history of SMA course with early onset, and the usage of gene therapy in most of the presymptomatic patients leads to the achievement of motor development milestones in accordance with WHO criteria.